Novozymes Management

How has Ester Baiget's remuneration changed compared to Novozymes's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr.29m	kr.10m	kr.3b
Sep 30 2023	n/a	n/a	kr.3b
Jun 30 2023	n/a	n/a	kr.3b
Mar 31 2023	n/a	n/a	kr.4b
Dec 31 2022	kr.24m	kr.10m	kr.4b
Sep 30 2022	n/a	n/a	kr.3b
Jun 30 2022	n/a	n/a	kr.3b
Mar 31 2022	n/a	n/a	kr.3b
Dec 31 2021	kr.24m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.3b
Dec 31 2020	kr.24m	kr.7m	kr.3b

Compensation vs Market: Ester's total compensation ($USD4.20M) is about average for companies of similar size in the Danish market ($USD4.19M).

Compensation vs Earnings: Ester's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Ester Baiget (52 yo)

4.3yrs

Tenure

kr.29,100,000

Compensation

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ester Baiget	President & CEO	4.3yrs	kr.29.10m	no data
Rainer Lehmann	Executive VP & CFO	less than a year	kr.6.40m	no data
Anders Lund	Chief Operating Officer	less than a year	kr.7.70m	no data
Claus Fuglsang	Chief Scientific Officer	3.7yrs	no data	no data
Tobias Bjorklund	Head of Investor Relations	no data	no data	no data
Winnie Bugel	General Counsel of Legal	less than a year	no data	no data
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	no data	no data
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.1yrs	no data	no data
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.3yrs	kr.7.60m	no data
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.1yrs	no data	no data
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	no data	no data
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	no data	no data

1.8yrs

Average Tenure

49.5yo

Average Age

Experienced Management: NSIS B's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jesper Brandgaard	Vice Chair of the Board	less than a year	no data	no data
Cornelis de Jong	Independent Chairman	4.3yrs	kr.1.78m	0.0011% DKK 2.1m
Kim Stratton	Independent Vice Chair	7.3yrs	kr.1.29m	no data
Kasim Kutay	Director	7.3yrs	kr.803.00k	0.00023% DKK 440.5k
Heine Dalsgaard	Director	4.3yrs	kr.1.07m	0.00065% DKK 1.2m
Lise Kaae	Director	less than a year	no data	no data
Anders Knudsen	Employee Representative Director	11.3yrs	kr.535.00k	no data
Sharon James	Independent Director	4.3yrs	kr.1.07m	no data
Anne Breum	Employee Representative Director	3.2yrs	kr.535.00k	0.00010% DKK 191.5k
Preben Nielsen	Employee Representative Director	3.2yrs	kr.803.00k	0.000090% DKK 172.4k
Jens Obro	Employee Representative Director	3.2yrs	kr.535.00k	0.00012% DKK 229.8k
Morten Otto Sommer	Independent Director	2.2yrs	kr.1.03m	0.00022% DKK 421.3k

3.7yrs

Average Tenure

59yo

Average Age

Experienced Board: NSIS B's board of directors are considered experienced (3.7 years average tenure).

Novozymes Management

Management criteria checks 2/4

Key information

Recent management updates

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Less than half of directors are independent

Recent updates

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent